Stockreport

ProKidney Reports Full Year 2025 Financial Results and Business Highlights

ProKidney Corp. - Class A Ordinary Shares  (PROK) 
PDF On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027In a July [Read more]